Evotec, Takeda partner on RNA-targeting drug discovery, development

By The Science Advisory Board staff writers

March 22, 2021 -- Evotec has entered into an alliance with Takeda Pharmaceutical with the goal of discovering and developing RNA-targeting small-molecule therapeutics for targets that are difficult to address with conventional approaches.

Together, the companies will jointly identify and develop small molecules targeting a range of RNA targets aligned with Takeda's research and development areas. The collaboration will leverage Evotec's RNA-targeting platform to optimally identify promising RNA sequences to target with small-molecule ligands that can potentially be developed into first-in-class therapeutics.

Evotec's platform uses structure-based recognition of RNA tertiary structures as an alternative to sequence-based approaches. RNA-targeting small-molecule approaches enable novel therapeutics by allowing highly conserved parts of RNA, creating pathways where encoded proteins cannot be targeted with conventional targeted approaches.

Under the agreement, Evotec will receive significant research funding and will be eligible to receive discovery, preclinical, clinical, commercial, and sales milestone payments of up to $160 million per program. Additionally, Evotec is entitled to tiered royalties on net sales of any product resulting from the collaboration.

Takeda to acquire Maverick Therapeutics
Takeda Pharmaceutical has exercised its option to purchase T cell-targeted immunotherapy developer Maverick Therapeutics for up to $525 million in...
Evozyne to develop synthetic proteins for Takeda gene therapies
Molecular engineering company Evozyne has signed a strategic collaboration and license agreement with Takeda Pharmaceutical. The partnership's aim is...
Eveotec, Indivumed partner on novel lung cancer therapies
Evotec and Indivumed announced on January 23 a partnership to collaborate on drug discovery and development of novel therapies for non-small cell lung...
Evotec, Bayer partner for drug discovery in women's health
Evotec and Bayer announced on January 9 the expansion of their partnership in women's health with a new five-year, multitarget collaboration with participation...
MilliporeSigma licenses CRISPR IP to Evotec
MilliporeSigma announced today that it signed a license agreement providing Evotec SE access to MilliporeSignma's foundational CRISPR intellectual protect....

Copyright © 2021 scienceboard.net


Conferences
CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter